Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply.
Publication
, Journal Article
Harskamp, RE; Alexander, JH; Lopes, RD
Published in: JAMA Cardiol
January 1, 2020
Duke Scholars
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
January 1, 2020
Volume
5
Issue
1
Start / End Page
111 / 112
Location
United States
Related Subject Headings
- Randomized Controlled Trials as Topic
- Percutaneous Coronary Intervention
- Network Meta-Analysis
- Humans
- Fibrinolytic Agents
- Atrial Fibrillation
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Harskamp, R. E., Alexander, J. H., & Lopes, R. D. (2020). Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. JAMA Cardiol, 5(1), 111–112. https://doi.org/10.1001/jamacardio.2019.4551
Harskamp, Ralf E., John H. Alexander, and Renato D. Lopes. “Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply.” JAMA Cardiol 5, no. 1 (January 1, 2020): 111–12. https://doi.org/10.1001/jamacardio.2019.4551.
Harskamp RE, Alexander JH, Lopes RD. Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. JAMA Cardiol. 2020 Jan 1;5(1):111–2.
Harskamp, Ralf E., et al. “Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply.” JAMA Cardiol, vol. 5, no. 1, Jan. 2020, pp. 111–12. Pubmed, doi:10.1001/jamacardio.2019.4551.
Harskamp RE, Alexander JH, Lopes RD. Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. JAMA Cardiol. 2020 Jan 1;5(1):111–112.
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
January 1, 2020
Volume
5
Issue
1
Start / End Page
111 / 112
Location
United States
Related Subject Headings
- Randomized Controlled Trials as Topic
- Percutaneous Coronary Intervention
- Network Meta-Analysis
- Humans
- Fibrinolytic Agents
- Atrial Fibrillation
- 3201 Cardiovascular medicine and haematology